Develops, manufactures, and sells regenerative medicine products for difficult-to-heal wounds and surgical and sports medicine applications to hospitals, wound care centers, and physician offices.
10-K for FY2025, filed Feb 26, 2026Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing, and sale of…View ↗
Our mission is advancing healing and recovery beyond expectations. Several of our existing and pipeline products in our portfolio have…View ↗
In the Advanced Wound Care market, we focus on the development and commercialization of products for the treatment of chronic and acute…View ↗
In the Surgical & Sports Medicine market, we are leveraging our broad regenerative medicine capabilities to address chronic and acute…View ↗
We focus our efforts on medical conditions that involve difficult-to-heal wounds and musculoskeletal injuries. Healing difficulties arise…View ↗
The company sells Advanced Wound Care and Surgical & Sports Medicine products; customers pay according to contract terms, with sales tied to shipment, the procedure date, or delivery.
10-K for FY2025, filed Feb 26, 2026The Company generates product revenue through the sale of Advanced Wound Care and Surgical & Sports Medicine products. There is a single…View ↗
10-K for FY2025, filed Feb 26, 2026
FY2025 revenue by product or service ↗$564.2M
10-K for FY2025, filed Feb 26, 2026
$564.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product revenue
Sold outright
10-K for FY2025, filed Feb 26, 2026 |
100% |
Net product revenue, FY2025
$563M Sources
|
Sold outright |
|
Grant income
|
0.2% |
Grant income, FY2025
$1.1M Sources
|
Hospitals and other care facilities, along with physician offices, buy its products. U.S. Advanced Wound Care sales are direct; Surgical & Sports Medicine uses direct representatives and independent agencies, and some overseas sales go through agents.
10-K for FY2025, filed Feb 26, 2026Our mission is advancing healing and recovery beyond expectations. Several of our existing and pipeline products in our portfolio have…View ↗
Our current Advanced Wound Care portfolio is sold throughout the United States via an experienced direct sales force. We use a mix of…View ↗
Sales generated by our direct sales forces in the United States have represented, and we anticipate will continue to represent, a majority…View ↗
Yes. It kept 7 cents of every revenue dollar as net income in FY2025, but spent more cash than it brought in: free cash flow was −$24.5M.
10-Q for Q3 FY2026, filed Nov 5, 2026
−$29.6MView ↗
10-Q for Q3 FY2026, filed Nov 5, 2026
Open tableView ↗
Growing. Revenue grew 21% in 4 years, from $467.4M in FY2021 to $564.2M in FY2025, about 5% a year.
Loading...